Checkmate Pharmaceuticals Stock

checkmatepharma.comHealthcare / BioTech & PharmaFounded: 2015Funding to Date: $82MM

Checkmate Pharmaceuticals is a clinical stage biopharmaceutical company focused on activation of innate immunity to treat cancer.

Register for Details

For more details on financing and valuation for Checkmate Pharmaceuticals, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Checkmate Pharmaceuticals.

Register Today

Team

Management Team

Art Krieg MD
Founder, Chief Scientific Officer & Board Member
David Mauro Ph.D
Chief Medical Officer
Karen Brennan
Chief Operations Officer
Kleem Chaudhary Ph.D
Chief Business Officer
James Wooldridge
Chief Medical Officer
Chuck Abdalian
Chief Financial Officer
Barry Labinger
Chief Executive Officer, Board Member & President

Board Members

Art Krieg MD
Keith Flaherty MD
Alan Fuhrman
Michael Powell Ph.D
Sofinnova Investments
Ben Auspitz
F-Prime Capital Partners
Corey Goodman Ph.D
venBio

Other companies like Checkmate Pharmaceuticals in the BioTech & Pharma sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$8.45B
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$8.84B
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$303.94MM
Sector
Last Round Est. Valuation
$4.74B

News Highlights

Checkmate Pharmaceuticals Announces Pricing of Initial Public Offering
CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI), a clinical stage biotechnology company focused on...
Checkmate Pharmaceuticals Raises $85M in Series C Financing
Checkmate Pharmaceuticals, a Cambridge, MA-based clinical stage biotechnology company with a novel approach to cancer immunotherapy, completed an $85m Series C financing
Checkmate Pharmaceuticals : Announces Additions to Management Team
Updated on: Sep 21, 2023